What to Do If You're Denied a Prescription Twice: Your Remaining Options
Two insurance denials triggers external independent review rights. Two prescriber denials means finding a platform with a different clinical framework. The complete map of remaining options.
Getting denied a GLP-1 prescription twice — by insurance or by prescribers — is frustrating and disorienting. Here's the complete map of remaining options, organized by what the denials were for.
If you've been denied by insurance twice
A second insurance denial after internal appeal makes your case eligible for external independent review — this is required by the ACA for most commercial plans and bypasses your insurer's internal process entirely. An independent organization (URAC-accredited IRO) reviews the clinical evidence and can overturn the denial. External review overturn rates for GLP-1 denials are significantly higher than for internal appeals — this step is underused.
After two insurance denials
- Request external independent review — this is a legal right for most ACA-compliant plans
- Your state insurance commissioner's office can facilitate if your insurer isn't cooperating
- File a complaint with your state insurance commissioner — creates regulatory pressure on the insurer
- Appeal through your employer's HR department if employer-sponsored (they negotiate with the insurer)
- Ask your prescriber about exception pathways specific to your plan
- Begin cash-pay through telehealth while external review proceeds
If two different prescribers declined to prescribe
Two prescriber refusals suggest either: your profile doesn't clearly meet prescribing criteria, or you haven't found a prescriber with a framework compatible with your situation.
If your BMI is below FDA eligibility thresholds: the options narrow. Off-label prescribing at lower BMI requires finding a prescriber willing to exercise clinical judgment outside the standard criteria — possible but requires finding a platform with that clinical philosophy.
The compounding safety net option
For patients who need to start medication while navigating insurance or prescriber challenges, compounded GLP-1 through a telehealth platform is the practical bridge. SkinnyRx at $179/month starting dose is the most accessible price point — note the FDA Warning Letter #717989 disclosure (marketing claims, Feb 2026) before choosing. SHED's compounded sublingual at $297–299/month is the alternative with no outstanding regulatory issues.
Verified telehealth providers
Sublingual semaglutide from $297/mo (increases to $399 at 7.5mg+). No prior auth.
Paid link Get started →Third-opinion telehealth consult — fresh clinical review of your eligibility.
Paid link Get started →